HIV Archives – Page 31 of 90 – Treatment Action Group

TAG’s Response to Sen. Cassidy Statements on AIDS Research Spending

November 20, 2015
Chad Cipiti

I would like to offer comments to correct the record on statements given by Senator Bill Cassidy (R-LA) at the October 7, 2015, hearing on the National Institutes of Health fiscal year 2016 budget. Several of his comments to the committee and NIH Director Francis Collins were incorrect or misleading. If his erroneous statements about AIDS research funding at the NIH are mistaken for fact, we will set a dangerous course for current and future research being conducted at the agency and undermine the prioritization process under way at the Office of AIDS Research (OAR).

HIV Cure Research Fact Sheet 2015

November 11, 2015
Chad Cipiti

Combination antiretroviral therapy (ART) is a highly effective treatment for HIV infection, preventing progression of the disease in the vast majority of recipients.

Story: New Breakthrough May Lead to HIV Relapse Cure

October 9, 2015
Dorrit Walsh

October 2015 Examples of media coverage: New Breakthrough May Lead to HIV Relapse Cure – Indo-Asian News Service, October 11, 2015 HIV breakthrough could lead to a CURE: Scientists identify markers on immune cells that ‘predict who can stop drug…

The Challenge of Defining HIV Remission

October 6, 2015
Chad Cipiti

Supportive regulatory guidance for cure research requires a clear understanding of all possible outcomes, including remission By Richard Jefferys The term remission is increasingly being invoked in the context of cure research and, by extension, is an issue for regulatory…

PrEP: The Pathway to Global Access

October 6, 2015
Chad Cipiti

Regulatory filing and review delays keep Truvada as pre-exposure prophylaxis out of reach of those who need it most By Scott Morgan Pre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent HIV acquisition. The U.S. Food and Drug…

TAGline Fall 2015

October 6, 2015
Chad Cipiti

In Defense of Stringency: In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products.

Fair Pricing Coalition Sign-on Letter to Gilead on Pricing of TAF

September 9, 2015
Chad Cipiti

Letter signed by a number of organizations and individuals urging Gilead to consider drug pricing that addresses the need for cost-contained HIV care delivery in the U.S.

Town Hall Meeting to Discuss Drastic Cuts to City’s HIV Testing and STD Screening Programs

August 31, 2015
Chad Cipiti

In response to disturbing trends in New York City’s response to the ongoing HIV and STD epidemics, ACT UP\New York and Treatment Action Group (TAG) will host a town hall meeting at the New York City

2015 Pipeline Report

July 17, 2015
Chad Cipiti

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Toward Comprehensive HIV Prevention Service Delivery in the United States: An Action Plan

June 24, 2015
Chad Cipiti

An objective of the National HIV/AIDS Strategy (NHAS), released by the White House in July 2010, is to lower the annual number of new infections in the United States by 25 percent by the end of 2015.